Through bulk dissection and genomic profiling of HER2-amplified and non-HER2 amplified components of clinically classified HER2-positive breast cancers, a recent study identified that the HER2-negative component of these tumours harboured additional driver mutations, including one case with an activating HER2 mutation, highlighting convergent evolution in this patient. Here, ERBB2 is linked to neoplasm.